MétaCan
← all works

New molecular assays for cancer diagnosis and targeted therapy.

2008· article· en· 8 citations· W2397537490 on OpenAlex

Why is this work in the frame?

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.

The three-model screen

all 1,000 screened works →

All three models called this out of scope.

stratum: aff_core · design weight: 5595.24 (the sample is stratified; any rate computed without the weight is wrong)
Claude Opus 4.8OUT
genre: other
about Canada: no
confidence: high

Review of molecular assays for cancer diagnosis and targeted therapy; the object is diagnostic technology and its clinical regulation.

GPT-5.6 (high)OUT
genre: conceptual
about Canada: no
confidence: high

The review concerns cancer diagnostic assays and treatments, not research methodology.

Grok 4.5OUT
genre: other
about Canada: no
confidence: high

Industry-oriented review of molecular diagnostic cancer assays and personalized medicine testing.

Abstract

Microarray multiplex protein measurement of biomarker-based molecular diagnostic and prognostic cancer testing assays is destined to become a large growth segment of the immunodiagnostic industry. Assays encompass immunohistochemistry, fluorescence in situ hybridization, ELISA and sequencing methods that must comply with stringent regulatory specifications. Current test services available range from single-site service-based assays to multi-laboratory testing. Some tests have regulatory approval, whereas others are regulated by the Clinical Laboratory Improvement Act or the College of American Pathologists, or both. Expectations of personalized medicine are building, and the future is expected to bring truly targeted treatments based on test results. In this review, biomarkers, screening, diagnosis, potential prognosis and treatment pertaining to colorectal, breast, and lung cancers are discussed and evaluated. Assay data are expected to improve clinical indices and treatment algorithms, leading to dynamic disease models for real-time, data-modulated patient management.

Stored with the screening record, where it is evidence for the labels above.

The record

Venue
PubMed
Topic
Advanced Biosensing Techniques and Applications
Field
Biochemistry, Genetics and Molecular Biology
Canadian institutions
Cytodiagnostics (Canada)
Funders
Keywords
Companion diagnosticMultiplexMedicineBiomarkerTargeted therapyColorectal cancerOncologyCancerBiomarker discoveryPrecision medicinePersonalized medicineLung cancerDiseaseDiagnostic testBreast cancerInternal medicineBioinformaticsPathologyProteomicsBiologyGene
Has abstract in OpenAlex
yes